Regeneron Forges a US$100 M Oncology Partnership with Bluebird Bio
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 8 (Table of Contents)
Published: 17 Aug-2018
DOI: 10.3833/pdr.v2018.i8.2349 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Pushing forward in its cancer immunotherapy research, Regeneron Pharmaceuticals has struck a deal with Bluebird Bio to develop new cancer cell therapies using Regeneron’s VelociSuite® platform technologies and Bluebird Bio’s gene therapy knowledge...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS